Oncolytics Biotech (ONCY) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
XBiotech (XBIT) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 14.9% versus a loss of 57.8%. Over five years, ONCY leads with a -77.8% price change compared with -84.9% for XBIT. Oncolytics Biotech is the larger company by market cap ($65.3 million vs $64.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONCY | XBIT |
|---|---|---|
| Share price | $0.4981 | $2.12 |
| Market cap | $65.31M | $64.63M |
| 1-day change | -9.04% | -1.85% |
| YTD return | -42.75% | -11.30% |
| 1-year return | -57.79% | -14.86% |
| 5-year return | -77.76% | -84.94% |
| Forward P/E | — | 16.31 |
| EPS (TTM) | $-0.35 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-28.76M | $-45.54M |
| 52-week high | $1.32 | $3.44 |
| 52-week low | $0.44 | $2.09 |
| Distance from 52-week high | -62.27% | -38.37% |
| Analyst consensus | buy | — |
| Avg. price target upside | +733.17% | — |
| Average volume | 1.09M | 42.87K |
| Shares outstanding | 131.12M | 30.49M |
| Employees | 29 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XBIT has outperformed ONCY by 42.9 percentage points over the past year.
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ONCY vs XBIT FAQ
Which is bigger, Oncolytics Biotech or XBiotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $65.31M compared with $64.63M for XBiotech (XBIT).
Which stock has performed better over the past year, ONCY or XBIT?
XBIT returned -14.86% over the past 12 months, compared with -57.79% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Oncolytics Biotech and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.